Results 71 to 80 of about 283,064 (357)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Engineering neuroblastoma models for clinical translation

Engineered Regeneration
Neuroblastoma is a profoundly heterogenous extracranial solid tumor in pediatric patients. Elevated risk grade of neuroblastoma has been correlated with unsatisfactory prognosis and resistance to chemotherapy.
Taiyu Song, Rui Liu, Feika Bian, Bin Kong, Jingjing Gan   +4 more
doaj   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.

PLoS ONE, 2014
Neuroblastoma, a tumor of the peripheral sympathetic nervous system, is the most common and deadly extracranial tumor of childhood. The majority of high-risk neuroblastoma exhibit amplification of the MYCN proto-oncogene and increased neoangiogenesis ...
Raul Calero, Esther Morchon, John Inge Johnsen, Rosario Serrano   +3 more
doaj   +1 more source

A 6-gene signature identifies four molecular subgroups of neuroblastoma [PDF]

, 2011
Background: There are currently three postulated genomic subtypes of the childhood tumour neuroblastoma (NB); Type 1, Type 2A, and Type 2B. The most aggressive forms of NB are characterized by amplification of the oncogene MYCN (MNA) and low expression ...
Daniel Dalevi (34357), Frida Abel (3966878), John Maris (6329228), Joëlle Vermeulen (7934234), Katleen De Preter (795), Maria Nethander (112766), Per Kogner (112796), Raymond L. Stallings (7926566), Raymond Stallings (7896044), Rebecka Jörnsten (3716419), Staffan Nilsson (112787)   +10 more
core   +2 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Emerging Neuroblastoma 3D In Vitro Models for Pre-Clinical Assessments

Frontiers in Immunology, 2020
The potential of tumor three-dimensional (3D) in vitro models for the validation of existing or novel anti-cancer therapies has been largely recognized.
Diana Corallo, Stella Frabetti, Olivia Candini, Elisa Gregianin, Massimo Dominici, Massimo Dominici, Horst Fischer, Sanja Aveic, Sanja Aveic   +8 more
doaj   +1 more source

Targeting of the MYCN protein with small molecule c-MYC inhibitors [PDF]

, 2014
This study was funded by grants from the Swedish Research Council and the Swedish Cancer Society. IM and HZ were recipients of graduate student grants from KI (KID), MAH was recipient of a Senior Investigator Award from the Swedish Cancer Society, and ...
Frenzel, Anna, Henriksson, Marie Arsenian, Larsson, Karin, Muller, Inga, Oliynyk, Ganna, Prochownik, Edward V., Westwood, Nicholas J., Zirath, Hanna   +7 more
core   +3 more sources

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source